# Intra-Cellular Therapies, Inc.  Share Price Target ‘$93.31’, now 20.7% Upside Potential

- Link: https://www.directorstalkinterviews.com/intra-cellular-therapies-inc.share-price-target-93.31-now-20.7-upside-potential/4121164697
- Published: 2024-07-12T14:38:57+01:00
- Author: Charlotte Edwards

**Intra-Cellular Therapies, Inc.** which can be found using ticker (ITCI) have now
15 market analysts covering the stock. The analyst consensus now points to a rating
of ‘buy’. The target price High/Low ranges between $120.00 and $65.00 calculating
the mean target share price we have $93.31. (at the time of writing). Given that
the stocks previous close was at $77.29 this would imply there is now a potential
upside of 20.7%. Also worth taking note is the 50 day moving average now sits at
$69.31 and the 200 day MA is $65.15. The total market capitalization for the company
now stands at 8.27B. The stock price for the company is currently $78.32 USD

 The potential market cap would be $9,982,484,784 based on the market consensus.

The company is not paying dividends at this time.

Other points of data to note are a P/E ratio of -, revenue per share of $5.34 and
a -11.23% return on assets.

Intra-Cellular Therapies, Inc. is a biopharmaceutical company. The Company is focused
on the discovery, clinical development and commercialization of small molecule drugs
that address underserved medical needs primarily in neuropsychiatric and neurological
disorders by targeting intracellular signaling mechanisms within the central nervous
system (CNS). The Company’s product CAPLYTA is a treatment for depressive episodes
associated with bipolar I or II disorder (bipolar depression) in adults as monotherapy
and as adjunctive therapy with lithium or valproate. The efficacy of CAPLYTA 42 
mg in bipolar depression was demonstrated in two positive Phase III placebo-controlled
bipolar depression studies, which evaluated the effects of CAPLYTA on depression
in adult patients with bipolar I or bipolar II disorder both as monotherapy (Study
404) and as adjunctive therapy with lithium or valproate (Study 402).

Share on: